On November 30, "Dongxing Medical," an investee company of Jifeng Capital—a sub-fund backed by the mother fund managed by Yuanhe Chencun—was listed on the ChiNext Board, with stock code: 301290.

Founded in 2001, Dongxing Medical specializes in the research, development, manufacturing, and sales of surgical medical devices, with a particular focus on anastomotic devices. The company has established a comprehensive industry-wide layout, spanning everything from product R&D and mold development to component production, product assembly, and ultimately, downstream sales. For years, Dongxing Medical has been deeply rooted in the field of minimally invasive surgical medical devices, steadily expanding its product portfolio through both organic growth and strategic external expansion. Starting as an agent for renowned domestic and international brands of surgical instruments, the company has evolved into a platform-based, group-level enterprise offering a diverse range of minimally invasive surgical equipment and tools—led by its high-end laparoscopic anastomotic devices and related accessories.

As of June 30, 2022, Dongxing Medical and its subsidiaries have established a robust patent portfolio, holding a total of 155 patents, including 23 invention patents. The company has also secured 43 medical device registration certificates and filing approvals, covering 3 Class I and 40 Class II medical device products. With the continuous improvement of healthcare services in China and the growing popularity of minimally invasive surgical procedures, the market for surgical medical devices such as staplers is experiencing significant growth. This trend presents Dongxing Medical with promising opportunities for expansion and development.

The funds raised from East Star Medical's IPO will be allocated to projects such as the "Zihang Medical Device Components Intelligent Manufacturing and Expansion Project," the "Wick Medical Minimally Invasive Surgery New Product Project," and the "Medical Surgical Instrument R&D Center Project."